secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001493152-24-039220
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharmaceuticals doses first patient in Phase 2 trial of NGC-Cap for metastatic breast cancer
--------------------------------------------------------------------------------

- First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.
- Phase 2 trial satisfies diligence milestone under license agreement with Elion Oncology for PCS6422; Condition Precedent date corrected to Oct 6, 2024.
- Three clinical sites with IRB approval activated; plans for ~30 sites worldwide.
- Interim analysis results from Phase 2 trial expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/0001493152-24-039220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224039220/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer